GlobeImmune Inc (GBIM)

0.00 USD  |  OTCM  |  Apr 25, 16:00
More

Price Chart

Key Stats

View All Stats
Price and Performance
Market Cap 0.00
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
All-Time High (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Month Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) --
Valuation
PE Ratio --
PE Ratio (Forward) Upgrade
PS Ratio --
Price to Book Value --
EV to EBITDA Upgrade
Dividend
Dividend --
Dividend Yield (Forward) Upgrade
Financials
Revenue (5 Year Growth) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (5 Year Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
Debt to Equity Ratio --
Return on Equity Upgrade
Return on Assets Upgrade
Risk
Beta (5Y) Upgrade
Max Drawdown (5Y) 100.00%

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

GlobeImmune Inc is a U.S.-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
URL https://globeimmune.com
Investor Relations URL https://www.globeimmune.com/investors/overview/
HQ State/Province Colorado
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

GlobeImmune Inc is a U.S.-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
URL https://globeimmune.com
Investor Relations URL https://www.globeimmune.com/investors/overview/
HQ State/Province Colorado
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A